Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on Feb 01, 2021 3:08pm
164 Views
Post# 32438926

SHARE THE STORY

SHARE THE STORY
A little more background on how tight the Ownership story is for SQI Diagnostics (SQD)....
 
Total Current Float ~ 330M Shares, w market cap of $120M CAD ($95M USD)
Approximate breakdown below....
 
Clive Beddoe (Chairman) ~ 86M = 26%
Gerold Connor (Director) ~ 86M = 26%
Wilmot Matthews (Director) ~ 87M = 26% 
Peter Lea (A Founder & Scientist) ~ 2M = 1% 
Other Insiders ~ 6M = 2%
 
Insiders represent over 80% of the float.  
 
Next seven groups own approx 11% of float
 
Top dozen groups represent over 90% of the float or approximately 305M shares.  
 
Remaining Float ~ 25M, or less than 10% of total shares.   
 
There is a very small percentage of the shares trading, among a very small group of handlers, determining SQI's value.  
The only reason handlers are able to prevail, is because the SQI story has not been shared.  
Given the names involved in this story they should not be allowing the value of our company to be manipulated by a few.     
SQI has significant assets that provide an amazing foundation for strong and enduring appreciation.   
The UHN & McMaster partnerships provide significant tailwinds that will quickly bare fruit.
Share our story.  Who benefits by keeping this a secret?  We have real lives at stake.
SHARE OUR STORY and HELP THE GLOBE.

<< Previous
Bullboard Posts
Next >>